Inotuzumab ozogamicin (CMC-544), an anti-CD22-calicheamicin ADC, has been extensively studied in patients with both indolent and aggressive B-cell NHL as well as acute leukemias [14]. This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.